* Apyx Medical Corp APYX.OQ APYX.O is expected to show a
rise in quarterly revenue when it reports results on August 12.
* The Clearwater, Florida-based company is expected to report
a 106.3% increase in revenue to $8.862 million from $4.3
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Apyx Medical Corp is
for a loss of 15 cents per share. For the same quarter last
year, the company reported a loss of 14 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by about 1.7%
in the last three months.
* Wall Street's median 12-month price target for Apyx Medical
Corp is $12, about 20.6% above its last closing price
of $9.53.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.14 -0.14 -0.14 Met 1.8
Dec. 31 2020 -0.11 -0.11 -0.04 Beat 64.3
Sep. 30 2020 -0.16 -0.17 -0.11 Beat 33.4
Jun. 30 2020 -0.20 -0.21 -0.14 Beat 34.1
Mar. -0.25 -0.25 -0.20 Beat 20
31 2020
Dec. 31 2019 -0.19 -0.16 Beat 17.2
Sep. 30 2019 -0.18 -0.18 -0.13 Beat 27.8
Jun. 30 2019 -0.17 -0.18 -0.13 Beat 27.8
This summary was machine generated August 10 at 13:57 GMT. All
figures in US dollars unless otherwise stated